Beauty Health (NASDAQ:SKIN) Upgraded by Zacks Research to Strong-Buy Rating

Beauty Health (NASDAQ:SKIN) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other equities analysts have also recently commented on SKIN. Canaccord Genuity Group reduced their target price on Beauty Health from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Friday, May 1st. TD Cowen dropped their price target on Beauty Health from $1.65 to $1.50 and set a “hold” rating for the company in a research report on Monday, March 16th. Roth Capital reissued a “buy” rating and set a $2.00 price objective (down from $2.50) on shares of Beauty Health in a report on Wednesday, May 20th. Finally, Weiss Ratings upgraded shares of Beauty Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $2.02.

Beauty Health Stock Up 2.7%

Shares of NASDAQ:SKIN opened at $0.86 on Monday. The firm has a fifty day moving average price of $0.72 and a two-hundred day moving average price of $1.00. The company has a market cap of $111.84 million, a price-to-earnings ratio of -5.08 and a beta of 1.08. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.79 and a quick ratio of 1.48. Beauty Health has a one year low of $0.55 and a one year high of $2.69.

Beauty Health (NASDAQ:SKIN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.04. Beauty Health had a negative net margin of 2.03% and a negative return on equity of 9.38%. The firm had revenue of $64.91 million for the quarter, compared to analysts’ expectations of $66.28 million. Analysts anticipate that Beauty Health will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Beauty Health

A number of large investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new stake in Beauty Health during the third quarter worth about $26,000. Franklin Resources Inc. purchased a new position in shares of Beauty Health during the 3rd quarter valued at about $31,000. Zacks Investment Management purchased a new position in shares of Beauty Health during the 3rd quarter valued at about $35,000. Ameriprise Financial Inc. bought a new stake in Beauty Health in the 3rd quarter worth approximately $38,000. Finally, Atom Investors LP bought a new stake in Beauty Health in the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Beauty Health Company Profile

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.